...
首页> 外文期刊>Medicine. >Intensity-modulated radiation therapy for patients with 1 to 3 brain metastases in recursive partitioning analysis class 3
【24h】

Intensity-modulated radiation therapy for patients with 1 to 3 brain metastases in recursive partitioning analysis class 3

机译:递归分析分析3级患者1至3例脑转移患者的强度调节放射治疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The prognosis is extremely poor for patients with brain metastases in recursive partitioning analysis (RPA) class 3. It is not clear whether dose elevation for brain lesions in addition to whole-brain radiotherapy could improve survival for those patients. This study aimed to assess the efficacy and safety of dose elevation with intensity-modulated radiation therapy (IMRT) for patients with 1 to 3 brain metastases in RPA class 3. From January 2013 to December 2015, 24 patients with 1 to 3 brain metastases in RPA class 3 were included in this study. The median age was 60 (range 41–85) years and the mean graded prognostic assessment (GPA) score was 1.25 (range 0.5–2). Whole-brain radiotherapy (30 Gy) with a simultaneous integrated boost (SIB) to the brain metastases (totaling 40 Gy) was delivered in 10 fractions using IMRT technique. Survival times and overall safety were assessed. The significance of prognostic variables on survival was assessed by both univariate and multivariate analyses. All of the patients completed the planned SIB schedule. The overall response rate was 66.7%. The median survival time (MST) was 8 months for the entire group of patients. The MST was 5 months for patients with a GPA score of 0.5 to 1 (n = 11 patients) and 12 months with a GPA score of 1.5 to 2 (n = 13 patients). No acute or late toxicities greater than grade 2 were detected. Age and subsequent chemotherapy were significantly associated with MST on univariate and multivariate analyses. It is feasible to elevate radiation doses to 40 Gy using the IMRT technique in RPA class 3 patients with 1 to 3 brain metastases without serious toxicities. The preliminary results are encouraging and further studies with larger cohorts are warranted.
机译:递归分配分析(RPA)类中脑转移患者的预后极差。目前尚不清楚脑病变的剂量升高是否除了全脑放射治疗,可改善这些患者的生存。本研究旨在评估患有强度调制的放射治疗(IMRT)的剂量升高的疗效和安全性,用于RPA级别3中的1至3级脑转移患者。2013年1月至2015年12月,24例患者1至3例脑转移本研究包括RPA级别3。中位年龄为60(41-85)岁,平均分级预后评估(GPA)得分为1.25(范围0.5-2)。使用IMRT技术在10个级分中递送与脑转移的全脑放射疗法(30GY)与脑转移(总共40μm)递送。评估生存时间和整体安全性。通过单变量和多变量分析评估预后变量对存活的重要性。所有患者都完成了计划的SIB计划。整体反应率为66.7%。中位生存时间(MST)为整个患者的8个月。对于GPA评分为0.5至1(n = 11名患者)和12个月的患者,MST为5个月,GPA得分为1.5至2(n = 13名患者)。没有检测到急性或晚期毒性超过2级。年龄和随后的化疗与单变量和多变量分析的MST显着相关。使用RPA类3患者的IMRT技术升高辐射剂量至40GY是可行的,其患有1至3例脑转移的IMRT技术,而没有严重毒性。初步结果是令人鼓舞的,并有权进一步研究较大的队列。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号